Search Results
Oct 20, 2025, 16:05 ET Washington Trust Reports Third Quarter 2025 Results
delivered strong in-market deposit growth, and prudently managed expenses," said Washington Trust Chairman and Chief Executive Officer Edward O. "Ned" Handy III. "We made several significant investments to drive future growth, including hiring a new senior executive with an extensive network and proven track
More news about: Washington Trust Bancorp, Inc.
Oct 20, 2025, 16:01 ET AGNC Investment Corp. Announces Third Quarter 2025 Financial Results
securities (GAAP measures), (ii) exclude retrospective "catch-up" adjustments to premium amortization cost due to changes in projected CPR estimates and (iii) include interest rate swap periodic income/ cost, TBA dollar roll income and other miscellaneous interest income/expense. As defined, net spread and
More news about: AGNC Investment Corp.
Oct 20, 2025, 15:19 ET Miami Fashion Week® Returns October 20-25, 2025 With a Lineup of Global Icons, Latin American Visionaries, and Miami Talent
international collaboration. Speakers and attendees included Lourdes Fernandez-Velasco (Executive Director, Miami Fashion Week), Commissioner Oliver G. Gilbert, III, Madeline Pumariega (Miami Dade College President), fashion designers, and more. Program Highlights
More news about: Miami Fashion Week
Oct 20, 2025, 10:04 ET FDA Approves Gazyva® (obinutuzumab) for the Treatment of Adults with Lupus Nephritis
living with this debilitating, chronic condition." The approval is based on positive results of the Phase II NOBILITY and Phase III REGENCY trials. In the REGENCY trial, nearly half (46.4%) of those treated with Gazyva in addition to standard therapy (mycophenolate mofetil and glucocorticoids)
More news about: Lupus Foundation of America, Inc.
Oct 20, 2025, 10:01 ET Diversis Capital Fund III Closes at $1.2 Billion Hard Cap
Fund III advances Diversis' strategy of accelerating the growth of software and tech-enabled companies Strong participation from diverse global base of new and existing institutional investors Fund III oversubscribed at hard cap
More news about: Diversis
Oct 20, 2025, 10:00 ET Girard Sharp Announces Proposed Settlements in the GWG Holdings, Inc. Securities Litigation
SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION AND PROPOSED SETTLEMENTS; (II) SETTLEMENT HEARING; AND (III) MOTION FORATTORNEYS' FEES AND EXPENSES TO: All Persons
More news about: Girard Sharp LLP
Oct 20, 2025, 10:00 ET Seasats Unveils The Quickfish: a High-Speed, Long-Endurance, Autonomous Surface Vessel Proven in US Navy Exercise
an $89M SBIR Phase III IDIQ contract to support NIWC Atlantic and USMC USV efforts.
More news about: Seasats
Oct 20, 2025, 10:00 ET North Square Investments Subadvisor Red Cedar Investment Management Surpasses $1 Billion in Assets Under Management in North Square Funds
original cost. "We are extremely pleased to be working in partnership with North Square," said John Cassady III, CFA, Managing Partner, Chief Executive Officer and Co-Chief Investment Officer of Red Cedar, "and delighted to see the growth in assets in the Funds
More news about: North Square Investments
Oct 20, 2025, 09:28 ET MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
IL-17F); (ii) SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; and (iii) SLK's distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy. The MoonLake
More news about: Robbins Geller Rudman & Dowd LLP
Oct 20, 2025, 09:05 ET CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
disease (based on RHB-104's positive Phase 3 Crohn's disease study results) and Phase 3-stage for pulmonary nontuberculous mycobacteria (NTM) disease; (iii) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, is in late-stage
More news about: Cumberland Pharmaceuticals Inc.
Oct 20, 2025, 09:00 ET RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
disease (based on RHB-104's positive Phase 3 Crohn's disease study results) and Phase 3-stage for pulmonary nontuberculous mycobacteria (NTM) disease; (iii) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, is in late-stage
More news about: RedHill Biopharma Ltd.
Oct 20, 2025, 09:00 ET Mountain Commerce Bancorp, Inc. Announces Third Quarter 2025 Results and Quarterly Cash Dividend
November 3, 2025. Management Commentary William E. "Bill" Edwards, III, Chief Executive Officer of the Company, commented as follows: "We are pleased to see our earnings continue to increase with adjusted
More news about: Mountain Commerce Bancorp, Inc.
Oct 20, 2025, 08:45 ET The Gross Law Firm Reminds Dow Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2025 - DOW
pricing pressures, softening global sales and demand for the Company's products, and an oversupply of products in the Company's global markets; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times. DEADLINE:
More news about: The Gross Law Firm
Oct 20, 2025, 08:45 ET Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact The Gross Law Firm
regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv)
More news about: The Gross Law Firm
Oct 20, 2025, 08:45 ET Investors in Fluor Corporation Should Contact The Gross Law Firm Before November 14, 2025 to Discuss Your Rights - FLR
hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iii) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was
More news about: The Gross Law Firm
Oct 20, 2025, 08:45 ET Shareholders of Nutex Health Inc. Should Contact The Gross Law Firm Before October 21, 2025 to Discuss Your Rights - NUTX
that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal
More news about: The Gross Law Firm
Oct 20, 2025, 08:37 ET Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
novel immunotherapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
More news about: Citius Oncology, Inc.
Oct 20, 2025, 08:31 ET LightPath Technologies Receives $4.8 Million Purchase Order for Advanced Infrared Camera Systems
awards, as well as any resulting impact on our financial performance; (ii) the impact of the G5 acquisition on our business and results of operations; (iii) the performance of our product portfolio and expected market potential with our products and (iv) expectations regarding our ability to secure government
More news about: LightPath Technologies
Oct 20, 2025, 08:30 ET BitMine Immersion (BMNR) Announces ETH Holdings Reaching 3.24 Million Tokens and Total Crypto and Cash Holdings of $13.4 Billion
BitMine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support BitMine's goal of acquiring 5% of ETH
More news about: BitMine Immersion Technologies, Inc.
Oct 20, 2025, 08:00 ET Huntington Bank Completes Merger with Veritex, Deepening Commitment to Texas
branches in its network. Huntington plans to maintain Veritex's branch network and invest to grow it over time. C. Malcolm Holland III, Veritex Holdings, Inc. president and CEO, has joined Huntington in a non-executive role as Chairman of Texas where he will continue his work to serve
More news about: Huntington Bancshares Incorporated
Oct 20, 2025, 08:00 ET Construction Partners, Inc. Completes Florida Acquisition
platform company, C.W. Roberts Contracting, Incorporated, which operates throughout the State of Florida. Fred J. (Jule) Smith, III, the Company's President and Chief Executive Officer, said, "This transaction expands our footprint into several markets and enhances our ability to
More news about: Construction Partners, Inc.
Oct 20, 2025, 08:00 ET AEA Private Debt Closes $550 Million Credit Continuation Vehicle, Led by Carlyle AlpInvest
income-generating portfolio of first-lien senior secured loans from AEA Private Debt's 2016 vintage direct lending fund – AEA Middle Market Debt Fund III – primarily consisting of loans to sponsor-backed U.S. middle market companies. Further enhancing long-term alignment between AEA Private Debt and its
More news about: AEA Investors
Oct 20, 2025, 06:30 ET IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
(i) the potential therapeutic benefits of IDEAYA therapeutics, including combination therapies; (ii) the safety and efficacy profile of darovasertib; (iii) the ongoing Phase 3 registrational trial (OptimUM-10) of darovasertib; (iv) the reporting of topline PFS data from the Phase2/3 (OptimUM-02) trial of
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 06:00 ET IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
related to (i) the potential therapeutic benefits of darovasertib, including in combination with crizotinib; (ii) the safety profile of darovasertib; (iii) the timing of reporting median PFS data from Phase 2/3 OptimUM-02 trial; and (iv) the potential for accelerated approval in 1L HLA*A2 negative mUM.
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 04:57 ET The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
October 20, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the results from the Phase III registrational clinical study OptiTROP-Lung04—led by Professor Zhang Li's team from Sun Yat-sen University Cancer Center—were published in the
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.